Gapping up
In reaction to earnings/guidance:
- LLNW +6.2%, PTON +6%, EDU +1.2%, NBHC +0.8%
Other news:
- VMAC +15.4% (shareholders approve business combination with Anghami)
- KURA +4.3% (received FDA authorization to proceed with KOMET-001 Phase 1b study)
- MESA +2.9% (reported 26,920 block hours in December 2021, +3.8% y/y)
- ALNY +2.7% (Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy)
- ELAN +1.7% (announces FDA approval of Zorbium)
- TREB +1.4% (receives shareholder approval for combination with System1)
Analyst comments:
- AMBP +2.7% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- AR +1.9% (upgraded to Buy from Neutral at Goldman)
- COTY +1.5% (upgraded to Buy from Neutral at DA Davidson)
- INO +1.5% (upgraded to Neutral from Underperform at BofA Securities)